var data={"title":"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/contributors\" class=\"contributor contributor_credentials\">Claire Shovlin, PhD, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/contributors\" class=\"contributor contributor_credentials\">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 30, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hereditary hemorrhagic telangiectasia (HHT; also called Osler-Weber-Rendu syndrome) is an autosomal dominant vascular disorder with a variety of clinical manifestations. Among the most common are epistaxis, gastrointestinal bleeding, and iron deficiency anemia, along with characteristic mucocutaneous telangiectasia. In addition, arteriovenous malformations (AVMs) commonly occur in the pulmonary, hepatic, and cerebral circulations, demanding knowledge of the risks and benefits of screening and treatment of patients with these complications.</p><p>The pathophysiology, epidemiology, and diagnosis of HHT will be reviewed here. The management of HHT is discussed in detail separately. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;</a>.)</p><p>Additional discussions of pulmonary AVMs, which affect over half of individuals with HHT, are also discussed separately. (See <a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-epidemiology-etiology-and-pathology-in-adults\" class=\"medical medical_review\">&quot;Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults&quot;</a> and <a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-clinical-features-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">&quot;Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults&quot;</a> and <a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">&quot;Therapeutic approach to adult patients with pulmonary arteriovenous malformations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DISEASE OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of epistaxis, gastrointestinal bleeding, and iron deficiency anemia associated with characteristic telangiectasia on the lips, oral mucosa, and fingertips (<a href=\"image.htm?imageKey=PULM%2F77416\" class=\"graphic graphic_picture graphicRef77416 \">picture 1</a>) has become firmly established as a medical entity. However, this constellation of findings underestimates the other, potentially life-threatening aspects of this disorder. It is now recognized that at least half of HHT patients have pulmonary involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/1-3\" class=\"abstract_t\">1-3</a>], more than one-third have hepatic involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/4,5\" class=\"abstract_t\">4,5</a>], and approximately 10 percent have cerebral involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/1,6,7\" class=\"abstract_t\">1,6,7</a>].</p><p>Individuals with HHT present to a wide range of clinicians spanning medical, surgical, general practice disciplines, and emergency departments, many of whom lack appreciation of the full range of consequences of the diagnosis of HHT for patients and their families [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H104272142\"><span class=\"h1\">INCIDENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidemiologic studies suggest likely prevalence rates of HHT between 1:5000 and 1:8000 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/9-13\" class=\"abstract_t\">9-13</a>], with much higher rates described in certain geographically isolated populations (eg, 1:1330 in Afro-Caribbean residents of Curacao and Bonaire [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/13\" class=\"abstract_t\">13</a>]). However, most patients are unaware of their diagnosis of HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. As a result, HHT has been subject to under-reporting [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PATHOPHYSIOLOGY</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Disease-causing DNA sequence variants in HHT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HHT is inherited as an autosomal dominant trait with varying penetrance and expression. Pathogenic variants in multiple genes can cause HHT, with three major disease genes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/16-19\" class=\"abstract_t\">16-19</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HHT1 is caused by pathogenic sequence variants in <em>ENG</em> (protein product: <strong>en</strong>do<strong>g</strong>lin, OMIM #187300).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HHT2 is due to pathogenic sequence variants in <em>ACVRL1</em> (protein product: <strong>ac</strong>ti<strong>v</strong>in <strong>r</strong>eceptor-<strong>l</strong>ike kinase 1, ALK-1, OMIM #600376).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JPHT is a juvenile polyposis-HHT overlap syndrome that accounts for approximately 1 percent of HHT cases and is due to pathogenic sequence variants in <em>SMAD4</em> (OMIM #175050) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p>More than 600 different HHT-causing mutations have been described with none particularly common [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/16\" class=\"abstract_t\">16</a>]. Further HHT genes are expected for classical HHT, while HHT-like syndromes have been associated with DNA sequence variants in <em>BMP9</em> (<em>GDF2</em>) and <em>RASA1</em> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/21-23\" class=\"abstract_t\">21-23</a>]. The University of Utah hosts the <a href=\"http://arup.utah.edu/database/HHT/&amp;token=EhO1sIjRC+QY0lbH/IIl+6RI2dgjzAAgMCcP1rNIiIv1uS91N+Fcn2yE+i3fdKg7&amp;TOPIC_ID=1345\" target=\"_blank\" class=\"external\">HHT mutation database</a> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H197304\"><span class=\"h2\">Genotype-phenotype correlations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All classical features of HHT can be seen in patients with HHT1, HHT2, and JPHT. Nevertheless, pulmonary and cerebral arteriovenous malformations (AVMs) are more common in HHT1 patients, while hepatic AVMs, hepatic AVM-associated pulmonary hypertension, and pulmonary arterial hypertension are more common in those with HHT2 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/25-29\" class=\"abstract_t\">25-29</a>].</p><p class=\"headingAnchor\" id=\"H24973965\"><span class=\"h2\">Cellular defects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is believed that most, if not all, cases of HHT result from endoglin or ALK-1 haploinsufficiency (ie, lack of sufficient protein for normal function), with the most consistent mechanism being the generation of a premature termination codon resulting in nonsense mediated decay of the mutant mRNA transcript [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/30\" class=\"abstract_t\">30</a>]. There is ongoing debate regarding whether vascular malformations result from local loss of <span class=\"nowrap\">endoglin/ALK-1</span> expression due to a conventional genetic &quot;second hit&quot; or other mechanism [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/31-33\" class=\"abstract_t\">31-33</a>].</p><p>Endoglin, ALK-1 and Smad4 proteins modulate signaling by the transforming growth factor (TGF)-beta superfamily, ligands for which include TGF-betas, activins, inhibins and bone morphogenetic proteins (BMPs). Endoglin and ALK-1 are transmembrane glycoproteins expressed abundantly on vascular endothelial cells. ALK-1 is a type I receptor for the superfamily; endoglin associates with different superfamily receptor complexes, and Smad4 lies downstream in signal transduction cascades.</p><p>In most cell types, TGF-beta 1 signalling via the type II receptor TbetaRII is propagated through ALK-5 (TbetaRI), although in endothelial cells, TbetaRII signalling can also be propagated through ALK-1 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/34\" class=\"abstract_t\">34</a>]. Endoglin can modify TGF-beta-1 signaling, but with the discovery of specific ligands for ALK-1, attention has also focused on bone morphogenetic protein (BMP) ligands BMP9 and BMP10 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/35\" class=\"abstract_t\">35</a>]. The pure pulmonary artery hypertension (PAH) phenotype seen in patients with HHT is indistinguishable from primary PAH in the general population, caused by pathogenic DNA sequence variants in <em>BMPR2</em>, which encodes the BMPRII protein that also associates with ALK-1. (See <a href=\"#H197304\" class=\"local\">'Genotype-phenotype correlations'</a> above and <a href=\"topic.htm?path=the-epidemiology-and-pathogenesis-of-pulmonary-arterial-hypertension-group-1#H2932921585\" class=\"medical medical_review\">&quot;The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)&quot;, section on 'Genetic mutations'</a>.)</p><p class=\"headingAnchor\" id=\"H2524536\"><span class=\"h2\">Vascular defects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with HHT can have vascular lesions in a variety of vascular beds, and the lesions can include arteriovenous shunts (eg, arteriovenous malformations <span class=\"nowrap\">[AVMs]/arteriovenous</span> fistulae [AVFs]) and telangiectasia.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Arteriovenous shunts</strong> &ndash; An arteriovenous shunt is a direct communication between arteries and veins. In anatomical shunts, abnormal vessels replace the normal capillary bed. These may be sacs (eg, for pulmonary AVMs), small collections of intervening vessels (nidal AVMs), or direct high-flow connection between the arterial and venous side (AVFs).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Telangiectasia</strong> &ndash; A telangiectasia is a small, dilated blood vessel (arteriole, venule, or capillary) that is apparent near the surface of skin or mucous membranes.</p><p/><p>These lesions can also be seen in other disorders besides HHT, or in otherwise healthy individuals, as part of a syndrome or in isolation. Additional vascular lesions such as aneurysms are increasingly recognized as part of the HHT phenotype.</p><p>Differing disease patterns in members of the same family in humans, as well as in mouse models, suggest that other genetic and environmental influences modify the HHT phenotype, and modifier genes are now described [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/36-38\" class=\"abstract_t\">36-38</a>]. Why AVMs develop in particular vascular beds and not others remains unclear and is the subject of ongoing research.</p><p>Several animal models of HHT have been described. Null mice for ENG and ACVRL1 die between embryonic day 10.5 to 11.5 because of gross vascular and cardiac defects [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/39\" class=\"abstract_t\">39</a>]. Heterozygous mice develop variable, but more HHT-specific, features including nosebleeds, telangiectasia, dilated vessels and AVMs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Conditional LoxP knockout alleles for all three HHT genes and for ALK-1 have been created; in animal models they cause HHT-like vascular malformations to occur in a consistent and predictable manner [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/42\" class=\"abstract_t\">42</a>].</p><p>There is substantial current interest in possible roles of vascular endothelial growth factor (VEGF) in HHT. Increased plasma levels of VEGF and TGF-beta-1 have been seen in HHT patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Furthermore, treatment with angiogenesis inhibitors has some efficacy in treating HHT. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H1340583712\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Systemic therapies'</a>.)</p><p>It is currently unclear whether VEGF is involved directly in the pathogenesis of what has been recognized as a TGF-beta superfamily disease, or whether these observations reflect the role of angiogenesis as a &quot;second hit&quot; phenomenon in HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/33,37\" class=\"abstract_t\">33,37</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H615291\"><span class=\"h2\">Overview of clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with HHT present to a wide range of clinicians spanning medical, surgical, general practice disciplines, and emergency departments, many of whom lack appreciation of the full range of consequences of the diagnosis of HHT for patients and their families [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/8\" class=\"abstract_t\">8</a>].</p><p>The majority of patients with HHT experience only epistaxis, mucocutaneous telangiectasia, and usually a tendency to develop iron deficiency anemia secondary to the blood losses [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/16,45,46\" class=\"abstract_t\">16,45,46</a>]. However, some patients can have substantial symptoms particularly attributable to severe recurrent nosebleeds <span class=\"nowrap\">and/or</span> gastrointestinal bleeding resulting in transfusion dependence. Visceral arteriovenous malformations (AVMs) are usually silent, but can cause major pathology: Pulmonary AVMs (PAVMs) allow systemic venous blood to bypass the normal pulmonary circulation, resulting in paradoxical embolic stroke, brain abscess, and migraines (<a href=\"image.htm?imageKey=HEME%2F63662\" class=\"graphic graphic_diagnosticimage graphicRef63662 \">image 1</a> and <a href=\"image.htm?imageKey=PULM%2F74593\" class=\"graphic graphic_table graphicRef74593 \">table 1</a>); cerebral AVMs can bleed and cause hemorrhagic stroke; hepatic AVMs can result in high output cardiac failure or other pathologies, and on occasion require liver transplantation. (See <a href=\"#H20480786\" class=\"local\">'Sites of large arteriovenous malformations'</a> below.)</p><p>The majority of children in HHT families are troubled only by epistaxis, but there are children who become symptomatic due to AVMs. As noted above, most, if not all, AVMs may be present in childhood (and in a series of 44 children screened in a multidisciplinary HHT center, 52 percent had hepatic AVMs, 45 percent PAVMs, and 16 percent cerebral AVMs) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"#H18820894\" class=\"local\">'Onset of disease manifestations'</a> below.)</p><p>Despite the evident mortality associated with HHT, life expectancy is surprisingly good, particularly in older individuals and in more recent series. Possible explanations are provided by relative protection from certain cancers, as might be predicted from the anticancer efficacy of antibodies that mimic the molecular basis of HHT (see <a href=\"#H3840081\" class=\"local\">'Cancer frequency'</a> below); and reduced rates of myocardial infarction [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/48\" class=\"abstract_t\">48</a>].</p><p class=\"headingAnchor\" id=\"H18820894\"><span class=\"h2\">Onset of disease manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HHT telangiectasia are not generally present at birth, but develop with increasing age. Screening programs that use imaging rather than clinical assessment identify AVMs earlier than the classical age-related prevalence studies, which were based on clinical signs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/39,49,50\" class=\"abstract_t\">39,49,50</a>]; in the imaging-based studies, approximately 70 percent of individuals developed some clinical sign of HHT by the age of 16 years, rising to over 90 percent by the age of 40 years. The following describe the findings from these more intensive screening programs:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epistaxis is usually the earliest sign of disease, often occurring in childhood.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mucocutaneous and gastrointestinal telangiectasia develop progressively with age [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/46,51\" class=\"abstract_t\">46,51</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary AVMs (PAVMs) generally become apparent after puberty, although they may be present during childhood, and a CT-based screening program indicated similar incidences in 74 children and 476 adults with HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age of development of cerebral vascular malformations appears to depend on type, with most thought to have developed during childhood [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p>There are specific times in patients' lives when their HHT pathologies become more hazardous, the most important of which is pregnancy, which results in a 1 percent risk of maternal death per pregnancy (due to PAVM hemorrhage, cerebral hemorrhage, and thrombotic complications), with all maternal deaths occurring in women previously considered well. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H675231792\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Pregnancy'</a>.)</p><p>There is also significant morbidity and mortality in younger patients, predominantly attributed to the consequences of visceral AVMs, especially pulmonary, cerebral, and hepatic AVMs, pulmonary hypertension, and venous thromboemboli. (See <a href=\"#H24974364\" class=\"local\">'Pulmonary hypertension'</a> below and <a href=\"#H12131106\" class=\"local\">'Venous thromboembolism'</a> below.)</p><p>Many of these risks were quantified by a prospective 30-year follow-up series in Denmark [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/11\" class=\"abstract_t\">11</a>] and a retrospective study of the parents of 74 Italian patients with HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/54\" class=\"abstract_t\">54</a>]. Even in these series dating back more than 30 years, for patients who did not present spontaneously to a clinician before the age of 60 years, there was no excess mortality [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Epistaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common clinical manifestation of HHT is spontaneous recurrent epistaxis from telangiectasia of the nasal mucosa. Some patients experience no or minimal occasional episodes, but for the majority, recurrent and frequent epistaxis is a feature, with many patients experiencing daily bleeds. In an online survey of 666 patients with HHT, 649 (97 percent) reported nosebleeds, and 326 (49 percent) reported the use of specialist invasive treatments for epistaxis, most requiring multiple different modalities [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/55\" class=\"abstract_t\">55</a>]. In another study of 220 patients with HHT, nearly half reported nosebleeds occurring daily, and three-quarters reported nosebleeds at least once a week [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/56\" class=\"abstract_t\">56</a>].</p><p>Epistaxis may be provoked by a variety of factors, such as changes in external temperature, humidity, activity and posture. Additional data also highlight the possibility of dietary aggravation of nosebleeds in patients with HHT (eg, from alcohol, spices, high salicylate dietary items, and migraine precipitating foods) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/55,56\" class=\"abstract_t\">55,56</a>].</p><p>Patients can present with hemodynamic disturbance secondary to acute blood loss, particularly for patients describing arterial rate bleeds (ie, gushing nosebleeds in the epistaxis severity score) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/57,58\" class=\"abstract_t\">57,58</a>]. Management and prevention of epistaxis can range from mild interventions, such as nasal humidification, to more aggressive measures, depending on the severity of bleeding. Iron supplementation is commonly needed, and blood transfusions may be required. These subjects are discussed in detail separately. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H2058197281\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Epistaxis'</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-epistaxis\" class=\"medical medical_review\">&quot;Approach to the adult with epistaxis&quot;</a> and <a href=\"topic.htm?path=management-of-epistaxis-in-children\" class=\"medical medical_review\">&quot;Management of epistaxis in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Gastrointestinal bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent gastrointestinal bleeding occurs in up to one-third patients with HHT, often presenting as iron deficiency anemia or an acute gastrointestinal bleeding episode, most commonly in patients over the age of 40 years [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/51,59\" class=\"abstract_t\">51,59</a>]. Gastrointestinal bleeding probably contributes less frequently to iron deficiency than under-recognized epistaxis. In many patients, improvement in nasal hemorrhage is able to significantly reduce iron and transfusion requirements.</p><p>Telangiectasia can occur throughout the gastrointestinal tract, and are more common in the stomach or duodenum than in the colon (<a href=\"image.htm?imageKey=GAST%2F50137%7EGAST%2F73541\" class=\"graphic graphic_picture graphicRef50137 graphicRef73541 \">picture 2A-B</a>). They are visualized by endoscopy and are similar in size and appearance to mucocutaneous telangiectasia, and may be surrounded by an anemic halo. Less commonly, AVMs and aneurysms occur; these lesions may be visualized on angiographic studies of the gastrointestinal tract (<a href=\"image.htm?imageKey=GAST%2F52754\" class=\"graphic graphic_diagnosticimage graphicRef52754 \">image 2</a>). (See <a href=\"topic.htm?path=angiodysplasia-of-the-gastrointestinal-tract\" class=\"medical medical_review\">&quot;Angiodysplasia of the gastrointestinal tract&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Mucocutaneous telangiectasia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Telangiectasia of the skin and buccal mucosa are present in most individuals in later life, but may be absent or subtle when younger [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/51\" class=\"abstract_t\">51</a>]. They mostly occur on the lips, tongue, buccal mucosa, and fingertips, but can occur elsewhere, where they are less HHT-specific and therefore not used for diagnostic purposes (<a href=\"image.htm?imageKey=PULM%2F77416\" class=\"graphic graphic_picture graphicRef77416 \">picture 1</a> and <a href=\"image.htm?imageKey=PEDS%2F52483\" class=\"graphic graphic_picture graphicRef52483 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/60\" class=\"abstract_t\">60</a>]. Bleeding can occur but is rarely clinically important. The main concern is cosmetic; short-term benefits may be obtained via laser or other ablation therapies.</p><p class=\"headingAnchor\" id=\"H20480786\"><span class=\"h2\">Sites of large arteriovenous malformations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinically important AVMs can occur in a number of organs, such as the lung, brain, and liver. While single AVMs can occur sporadically in the normal population as well as in patients with HHT, the presence of multiple AVMs in an organ such as the lung or brain make a sporadic etiology less likely [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14,61\" class=\"abstract_t\">14,61</a>]. However, single AVMs are still strongly associated with HHT in both organs. Additionally, CT-based research screening programs of asymptomatic individuals have identified pancreatic AVMs at surprisingly high frequency [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/62\" class=\"abstract_t\">62</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Pulmonary AVMs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary arteriovenous malformations (PAVMs) are thin-walled abnormal vessels that replace normal capillaries between the pulmonary arterial and venous circulations, often resulting in bulbous sac-like structures (<a href=\"image.htm?imageKey=PULM%2F56072\" class=\"graphic graphic_diagnosticimage graphicRef56072 \">image 3</a> and <a href=\"image.htm?imageKey=PULM%2F54651\" class=\"graphic graphic_diagnosticimage graphicRef54651 \">image 4</a>). They provide a direct capillary-free communication between the pulmonary and systemic circulations. Pulmonary arterial blood passing through these right-to left shunts cannot be oxygenated, leading to hypoxemia. Hypoxemia results in a polycythemic stimulus, which can lead to clinically significant levels of secondary polycythemia.</p><p>The clinical features, diagnosis, screening for, and treatment of PAVMs are discussed in detail separately. (See <a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-clinical-features-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">&quot;Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults&quot;</a> and <a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-epidemiology-etiology-and-pathology-in-adults\" class=\"medical medical_review\">&quot;Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults&quot;</a>.)</p><p>Summarized briefly, the majority of patients with PAVMs have no respiratory symptoms, and most are unaware that they have HHT or PAVMs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14,63\" class=\"abstract_t\">14,63</a>]. In one review, fewer than one-third of affected individuals exhibited physical signs indicating a substantial right-to-left shunt (eg, cyanosis, clubbing, and polycythemia) (<a href=\"image.htm?imageKey=HEME%2F54074\" class=\"graphic graphic_table graphicRef54074 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/64\" class=\"abstract_t\">64</a>]. These proportions are likely to fall still further as more patients are diagnosed with more sensitive screening programs.</p><p>Patients with PAVMs are at risk for complications, most commonly neurological sequelae due to paradoxical embolism, with embolic material evading the filtering function of the pulmonary capillaries and reaching the central nervous system. Catastrophic embolic cerebral events (cerebral abscess and embolic stroke), and transient ischemic attacks occur in patients with clinically silent PAVMs, and carry significant morbidity and mortality, indicating the need for early diagnosis and intervention (eg, embolization of PAVMs; antibiotic prophylaxis for interventional procedures, especially dental) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14,65\" class=\"abstract_t\">14,65</a>]. In a 2017 study of 445 consecutive adults with HHT and CT-confirmed PAVMs, 37 (8.3 percent) had brain abscesses [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/66\" class=\"abstract_t\">66</a>]. By multivariate logistic regression, brain abscess was associated with low oxygen saturation (indicated greater right-to-left shunt), higher transferrin saturation, intravenous use of iron for anemia, male sex, and venous thromboemboli. There were no relationships between the anatomic attributes of PAVMs and the likelihood of brain abscess. (See <a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations#H22767252\" class=\"medical medical_review\">&quot;Therapeutic approach to adult patients with pulmonary arteriovenous malformations&quot;, section on 'Natural history'</a> and <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H2324314219\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Pulmonary AVMs'</a>.)</p><p>In addition, hemorrhage may occur from the fragile PAVM vessels into a bronchus or the pleural cavity, causing hemoptysis or hemothorax, respectively. However, this is rare outside of pregnancy [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14,67\" class=\"abstract_t\">14,67</a>]. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H675231792\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Pregnancy'</a>.)</p><p>An increased prevalence of migraine has been described in PAVM patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/68\" class=\"abstract_t\">68</a>], a finding that has also been associated with right-to-left shunting due to a patent foramen ovale. (See <a href=\"topic.htm?path=pathophysiology-clinical-manifestations-and-diagnosis-of-migraine-in-adults#H140724624\" class=\"medical medical_review\">&quot;Pathophysiology, clinical manifestations, and diagnosis of migraine in adults&quot;, section on 'Right-to-left cardiac shunt'</a>.)</p><p>Management of PAVMs is presented in detail separately, including screening, embolization, and the use of prophylactic antibiotics to reduce the role of brain abscess. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H2324314219\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Pulmonary AVMs'</a> and <a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">&quot;Therapeutic approach to adult patients with pulmonary arteriovenous malformations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Cerebral AV shunts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HHT may have cerebral or spinal cord involvement. Cerebrovascular malformations include classical nidal AVMs, micro AVMs (nidus &lt;1 cm), high flow arteriovenous fistulae (AVFs; generally found in children), and telangiectasias. Spinal AVFs are especially suggestive of the diagnosis. The prognosis depends upon the type and location of the lesion [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/53\" class=\"abstract_t\">53</a>]. Other pathology can occur as in the general population (<a href=\"image.htm?imageKey=NEURO%2F75190\" class=\"graphic graphic_picture graphicRef75190 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/53,69\" class=\"abstract_t\">53,69</a>].</p><p>Cerebral AV shunts affect approximately 10 percent of HHT patients, are often multiple, and are usually silent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/1,6,61,70\" class=\"abstract_t\">1,6,61,70</a>]. High-flow shunts through AVFs in young infants can present with systemic circulatory overload or hydrovenous dysfunction (eg, macrocephaly, hydrocephalus). Other presentations include seizures, ischemia of the surrounding tissue due to a steal effect, or hemorrhage. The latter may be less frequent than that seen in non-HHT cerebral AVMs, in part due to the lower frequency of associated aneurysms. (See <a href=\"topic.htm?path=vascular-malformations-of-the-central-nervous-system#H9\" class=\"medical medical_review\">&quot;Vascular malformations of the central nervous system&quot;, section on 'Capillary telangiectasias'</a>.)</p><p>Cerebral hemorrhage often has devastating effects. Thus, patients with symptoms suggestive of cerebral AV shunts deserve further assessment as in the non-HHT population, including noninvasive imaging and ultimately assessment by experienced neurointerventional centers. The question of screening asymptomatic individuals with HHT for cerebral AV shunts remains controversial in HHT as in the general population [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/71\" class=\"abstract_t\">71</a>]. Since the 2014 publication of the ARUBA trial, which demonstrated an increased risk of bleeding with treatment of asymptomatic AV shuts, many more countries restrict screening to symptomatic patients or only perform screens after pretest counselling of patients. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H3647832702\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Cerebral lesions'</a> and <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H2563903851\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Cerebral AV shunt screening'</a>.)</p><p>Cerebral magnetic resonance imaging (MRI) is the most sensitive noninvasive test (<a href=\"image.htm?imageKey=NEURO%2F53992\" class=\"graphic graphic_diagnosticimage graphicRef53992 \">image 5</a>). Difficulties are incurred in screening settings for patients with PAVMs that were embolized when embolization devices used metal-containing materials that were not designated MRI-compatible.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Hepatic involvement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatic involvement occurs in up to two-thirds of patients with HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/4,5,72,73\" class=\"abstract_t\">4,5,72,73</a>]. However, guidance from a 2016 document emphasizes that this is usually silent, and screening is not recommended unless symptoms are present [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/74\" class=\"abstract_t\">74</a>]. When symptoms occur, these most commonly relate to development of high-output heart failure, portal hypertension, or biliary disease, reflecting different patterns of vascular involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/75-77\" class=\"abstract_t\">75-77</a>]. Large AVMs between the hepatic artery and hepatic vein can cause a significant left-to-right shunt with increased cardiac output that, particularly when combined with anemia, places patients at risk of angina and heart failure [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/75,78\" class=\"abstract_t\">75,78</a>]. (See <a href=\"topic.htm?path=hepatic-hemangioma\" class=\"medical medical_review\">&quot;Hepatic hemangioma&quot;</a>.)</p><p>Portal hypertension and hepatic encephalopathy, particularly after episodes of gastrointestinal bleeding, may result both from shunts between the hepatic artery and portal vein, and from increased sinusoidal blood flow, leading to enhanced deposition of fibrous tissue and pseudocirrhosis of the liver [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/75,79\" class=\"abstract_t\">75,79</a>].</p><p>Hepatic AVMs may be suspected in patients with HHT who have hepatomegaly, a liver bruit, or abnormal liver function tests. The diagnosis can be established by computed tomography, MRI, Doppler ultrasonography, or angiography [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/80\" class=\"abstract_t\">80</a>]. Liver biopsy is not recommended as it is not useful in the diagnosis of HHT and may be complicated by bleeding [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/76\" class=\"abstract_t\">76</a>].</p><p>The natural history of hepatic AVMs was studied in 154 patients with HHT and hepatic vascular malformations who were followed over a median period of 44 months (range: 12 to 181 months) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/81\" class=\"abstract_t\">81</a>]. Eight (5.2 percent) died from vascular malformation-related complications and 39 (25.3 percent) experienced non-fatal complications. The average incidence rates of death and complications were 1.1 and 3.6 per 100 person-years, respectively, while the rate of complete response to therapy was 63 percent. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H3247131828\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Hepatic AVMs'</a>.)</p><p class=\"headingAnchor\" id=\"H1398318828\"><span class=\"h2\">Iron deficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, epistaxis and gastrointestinal bleeding can be sufficient to cause iron deficiency and iron deficiency anemia. Screening and management is presented separately. (See <a href=\"topic.htm?path=iron-deficiency-in-infants-and-children-less-than12-years-treatment\" class=\"medical medical_review\">&quot;Iron deficiency in infants and children &lt;12 years: Treatment&quot;</a> and <a href=\"topic.htm?path=iron-requirements-and-iron-deficiency-in-adolescents\" class=\"medical medical_review\">&quot;Iron requirements and iron deficiency in adolescents&quot;</a> and <a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">&quot;Treatment of iron deficiency anemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H24974364\"><span class=\"h2\">Pulmonary hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary hypertension is not a single disease entity, and can result from multiple causes in HHT. Pulmonary hypertension in HHT is usually due to increased pulmonary flow due to systemic AVMs <span class=\"nowrap\">and/or</span> anemia [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/82\" class=\"abstract_t\">82</a>]. However, it may be due to a pure pulmonary arterial hypertension (PAH) phenotype indistinguishable from PAH in the general population [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/16,83\" class=\"abstract_t\">16,83</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of pulmonary hypertension in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12131106\"><span class=\"h2\">Venous thromboembolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HHT are at increased risk of venous thromboemboli, the management of which can be compounded by other aspects of their HHT, as clinicians often consider that treatment or prophylaxis with anticoagulants is contraindicated in HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/84\" class=\"abstract_t\">84</a>]. In a study of 609 patients with HHT recruited prospectively in two separate series at a single center, low serum iron levels, attributed to inadequate replacement of hemorrhagic iron losses, were associated with elevated plasma levels of coagulation factor VIII and an increased venous thromboembolic (VTE) risk [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/85\" class=\"abstract_t\">85</a>].</p><p>In each series, there was an inverse association between factor VIII levels and serum iron that persisted after adjustment for age, inflammation, <span class=\"nowrap\">and/or</span> von Willebrand factor. Low serum iron levels were also associated with VTE: the age-adjusted odds ratio [OR] of 0.91 (95% CI 0.86-0.97) per 1 <span class=\"nowrap\">micromol/L</span> increase in serum iron implied a 2.5-fold increase in VTE risk for a serum iron of 6 <span class=\"nowrap\">micromol/L</span> compared with the mid-normal range (17 <span class=\"nowrap\">micromol/L)</span>. The association appeared to depend upon factor VIII levels, as once adjusted for factor VIII levels, the association between VTE and iron was no longer evident.</p><p class=\"headingAnchor\" id=\"H3839692\"><span class=\"h2\">Arterial thromboses and platelets</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Iron deficiency is also emerging as a strong risk factor for ischemic stroke in HHT patients with pulmonary AVMs (PAVMs). In a series of 497 consecutive patients with HHT and CT-proven PAVMs, the risk of stroke decreased as serum iron increased (adjusted OR 0.96 per <span class=\"nowrap\">mg/mL</span> increase in serum iron; 95% CI 0.92-1.00) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/86\" class=\"abstract_t\">86</a>]. The actual platelet count did not differ in patients with and without strokes. This finding means that for the same PAVMs, the stroke risk would approximately double with serum iron 6 <span class=\"nowrap\">micromol/L</span> compared with mid-normal range (eg, 7 to 27 <span class=\"nowrap\">micromol/L)</span> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/86\" class=\"abstract_t\">86</a>]. This study in HHT patients confirmed data from the 1970s in non-HHT patients that iron deficiency is also associated with exuberant platelet aggregation in response to 5-hydroxytryptamine (5HT) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/87\" class=\"abstract_t\">87</a>].</p><p class=\"headingAnchor\" id=\"H3839749\"><span class=\"h2\">Migraines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Migraines are more common in HHT patients than in patients without HHT [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/88-90\" class=\"abstract_t\">88-90</a>]. Migraine features and precipitants appear indistinguishable from migraines in the general population [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/56\" class=\"abstract_t\">56</a>]. Multiple studies demonstrate that the risk of migraine in HHT patients is approximately doubled by the presence of PAVMs, and there is evidence that migraines improve following PAVM treatment [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/56,68,90-93\" class=\"abstract_t\">56,68,90-93</a>].</p><p class=\"headingAnchor\" id=\"H3840081\"><span class=\"h2\">Cancer frequency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The frequency of various cancer types in patients with HHT versus controls has been studied. A survey of cancer frequency in patients with HHT over 60 years and age-matched controls showed that despite the predisposition to gastrointestinal cancers conferred by SMAD4 mutation in some patients, age-adjusted rates of cancer were similar in individuals with HHT versus controls (OR 1.04; 95% CI 0.90-1.21) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/94\" class=\"abstract_t\">94</a>]. Evaluation of common cancer types revealed a lower incidence of lung cancer (OR 0.48; 95% CI 0.30-0.70); an increase in early, but fewer late onset colorectal cancers; no difference in prostate cancer; and a higher incidence of breast cancer (OR 1.52; 95% CI 1.07-2.14). The increase in breast cancer was speculatively attributed to thoracic radiation exposure. A subsequent study of 246 PAVM patients demonstrated that protocols for diagnosis, treatment, and follow-up result in levels of radiation exposure that would be classified as harmful, particularly in patients with underlying HHT; the mean cumulative effective dose (CED) of radiation over an 11-year period was 51.7mSv, and in 26 patients, CED exceeded 100mSv [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/95\" class=\"abstract_t\">95</a>]. CT scans accounted for 46 percent of the CED, and interventional procedures accounted for 51 percent.</p><p class=\"headingAnchor\" id=\"H323011\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine coagulation and platelet counts are normal in HHT in general &ndash; the hemorrhagic phenotype results from the vascular abnormalities and not a hemorrhagic diathesis.</p><p>Anemia with evidence of iron deficiency is common, especially in those with insufficient iron supplementation. In people with HHT, iron deficiency is associated with marginal increases in platelet counts, as seen in the general population, though the platelet count exceeded <span class=\"nowrap\">400,000/microL</span> in only 35 of 465 individuals (7.5 percent) and exceeded <span class=\"nowrap\">500,000/microL</span> only in 7 individuals (1.5 percent), and there was no association with ischemic stroke. Iron deficiency is also associated with elevated factor VIII levels and a shortened activated partial thromboplastin time (aPTT) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/86,96\" class=\"abstract_t\">86,96</a>]; these findings are associated with an increased prevalence of venous thromboembolism (VTE) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/85\" class=\"abstract_t\">85</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presence of HHT may be suspected in patients with the above clinical manifestations, particularly if there is a first-degree relative with HHT. (See <a href=\"#H8\" class=\"local\">'Clinical features'</a> above.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Consensus criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>International consensus diagnostic criteria (the Cura&ccedil;ao diagnostic criteria) are based upon the following four findings [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/97,98\" class=\"abstract_t\">97,98</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Spontaneous and recurrent epistaxis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple mucocutaneous telangiectasia at characteristic sites</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Visceral involvement (eg, gastrointestinal telangiectasia; pulmonary, cerebral, or hepatic arteriovenous malformations [AVMs])</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A first-degree relative with HHT</p><p/><p>These criteria define &quot;definite&quot; (3+ criteria), &quot;suspected&quot; (2 criteria), and &quot;unlikely&quot; (1 criterion). These have been validated by molecular studies; in probands who met the strictly applied criteria in an HHT Center of Excellence, 137 of 141 (97.2 percent) were found to have a mutation in either endoglin (66 of 141 [46.8 percent]), ACVRL1 (69 of 141 [48.9 percent]), or SMAD4 (2 of 141 [2.8 percent]) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/99\" class=\"abstract_t\">99</a>].</p><p>The diagnosis may be confirmed by identification of a pathogenic sequence variant in <em>ENG</em>, <em>ACVRL1</em>, or SMAD4, although this is not required to make a diagnosis of HHT. Gene testing does not detect all mutations that might be present and care is required not to over-interpret sequence variants that are not disease-causing.</p><p>Several centers for genetic testing are available in different countries, with details available through the HHT Foundation International website [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/100\" class=\"abstract_t\">100</a>]. Previously reported variants (pathogenic, variants of unknown significance, and benign) are registered on the HHT mutation database, available at <a href=\"http://arup.utah.edu/database/HHT/&amp;token=EhO1sIjRC+QY0lbH/IIl+6RI2dgjzAAgMCcP1rNIiIv1uS91N+Fcn2yE+i3fdKg7&amp;TOPIC_ID=1345\" target=\"_blank\" class=\"external\">http://arup.utah.edu/database/HHT/</a> [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/24\" class=\"abstract_t\">24</a>]. The classification of variants and determination of significance is discussed in more detail separately. (See <a href=\"topic.htm?path=secondary-findings-from-genetic-testing#H70129\" class=\"medical medical_review\">&quot;Secondary findings from genetic testing&quot;, section on 'Definitions and classification of variants'</a>.)</p><p class=\"headingAnchor\" id=\"H12130735\"><span class=\"h1\">RESOURCES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Educational materials for patients with HHT, and the location of specialized centers for diagnosing and managing HHT and pulmonary arteriovenous malformations (PAVMs) are available from <a href=\"http://curehht.org/&amp;token=a7/GN7K9S0SGpcQnma44kR3Syk+NVaQ+v9WECcchB+8=&amp;TOPIC_ID=1345\" target=\"_blank\" class=\"external\">Cure HHT</a> and other patient groups.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=arteriovenous-malformations-in-the-brain-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Arteriovenous malformations in the brain (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H30\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with a prevalence of 1:5000 to 1:8000. Many individuals with HHT are unaware of their disease. Although HHT is hereditary, clinical manifestations are not generally present at birth, but develop with increasing age. Epistaxis is usually the earliest sign of disease, often occurring in childhood; pulmonary arteriovenous malformations (PAVMs) generally become symptomatic after puberty. (See <a href=\"#H2\" class=\"local\">'Disease overview'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with HHT may be asymptomatic or have a wide spectrum of clinical manifestations ranging from minimal to life-threatening. The most common clinical findings are epistaxis and iron deficiency anemia from bleeding. Visceral arteriovenous malformations (AVMs) of the liver, lung, and central nervous system are common, while usually asymptomatic, complications include high output heart failure, portal hypertension, liver failure, hemoptysis, polycythemia, cerebral abscess, and stroke. (See <a href=\"#H8\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>International consensus diagnostic criteria for HHT are based upon the following four criteria:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Spontaneous and recurrent nosebleeds</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Multiple mucocutaneous telangiectasia at characteristic sites</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Visceral involvement (eg, gastrointestinal, pulmonary, cerebral, or hepatic AVMs)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A first degree relative with HHT</p><p/><p class=\"bulletIndent1\">These criteria define &quot;definite,&quot; &quot;suspected,&quot; and &quot;unlikely&quot; HHT when three or four, two, or zero to one of the criteria are present, respectively. The diagnosis may also be confirmed by formal genetic testing for mutations involving endoglin, ALK-1, or SMAD4. (See <a href=\"#H15\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of HHT, including treatment of specific vascular lesions and screening of asymptomatic individuals for PAVMs, is discussed in detail separately. (See <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H583517746\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate would like to acknowledge Vijeya Ganesan, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/1\" class=\"nounderline abstract_t\">Haitjema T, Disch F, Overtoom TT, et al. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995; 99:519.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/2\" class=\"nounderline abstract_t\">Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169:994.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/3\" class=\"nounderline abstract_t\">van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138:833.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/4\" class=\"nounderline abstract_t\">Piantanida M, Buscarini E, Dellavecchia C, et al. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996; 33:441.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/5\" class=\"nounderline abstract_t\">McDonald JE, Miller FJ, Hallam SE, et al. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000; 93:320.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/6\" class=\"nounderline abstract_t\">Fulbright RK, Chaloupka JC, Putman CM, et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 1998; 19:477.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/7\" class=\"nounderline abstract_t\">Brinjikji W, Iyer VN, Yamaki V, et al. Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years. AJNR Am J Neuroradiol 2016; 37:1479.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/8\" class=\"nounderline abstract_t\">Gallitelli M, Pasculli G, Fiore T, et al. Emergencies in hereditary haemorrhagic telangiectasia. QJM 2006; 99:15.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/9\" class=\"nounderline abstract_t\">Bideau A, Plauchu H, Brunet G, Robert J. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. Popul 1989; 44:3.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/10\" class=\"nounderline abstract_t\">Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19:140.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/11\" class=\"nounderline abstract_t\">Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245:31.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/12\" class=\"nounderline abstract_t\">Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/13\" class=\"nounderline abstract_t\">Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003; 116A:324.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/14\" class=\"nounderline abstract_t\">Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63:259.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/15\" class=\"nounderline abstract_t\">Donaldson JW, McKeever TM, Hall IP, et al. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax 2014; 69:161.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/16\" class=\"nounderline abstract_t\">Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17:860.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/17\" class=\"nounderline abstract_t\">Berg JN, Gallione CJ, Stenzel TT, et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997; 61:60.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/18\" class=\"nounderline abstract_t\">McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/19\" class=\"nounderline abstract_t\">Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13:189.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/20\" class=\"nounderline abstract_t\">Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/21\" class=\"nounderline abstract_t\">Wooderchak-Donahue WL, McDonald J, O'Fallon B, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013; 93:530.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/22\" class=\"nounderline abstract_t\">Hernandez F, Huether R, Carter L, et al. Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. Hum Genome Var 2015; 2:15040.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/23\" class=\"nounderline abstract_t\">Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006; 140:2155.</a></li><li class=\"breakAll\">http://arup.utah.edu/database/HHT/ (Accessed on August 29, 2012).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/25\" class=\"nounderline abstract_t\">Kjeldsen AD, M&oslash;ller TR, Brusgaard K, et al. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med 2005; 258:349.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/26\" class=\"nounderline abstract_t\">Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006; 43:371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/27\" class=\"nounderline abstract_t\">Sabb&agrave; C, Pasculli G, Lenato GM, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/28\" class=\"nounderline abstract_t\">Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007; 9:14.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/29\" class=\"nounderline abstract_t\">Bossler AD, Richards J, George C, et al. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006; 27:667.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/30\" class=\"nounderline abstract_t\">Govani FS, Giess A, Mollet IG, et al. Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia. Mol Syndromol 2013; 4:184.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/31\" class=\"nounderline abstract_t\">Bourdeau A, Cymerman U, Paquet ME, et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000; 156:911.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/32\" class=\"nounderline abstract_t\">Arthur H, Geisthoff U, Gossage JR, et al. Executive summary of the 11th HHT international scientific conference. Angiogenesis 2015; 18:511.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/33\" class=\"nounderline abstract_t\">Gkatzis K, Thalgott J, Dos-Santos-Luis D, et al. Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations. Arterioscler Thromb Vasc Biol 2016; 36:707.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/34\" class=\"nounderline abstract_t\">Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128:585S.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/35\" class=\"nounderline abstract_t\">Bailly S. HHT is not a TGF-beta disease. Blood 2008; 111:478.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/36\" class=\"nounderline abstract_t\">Benzinou M, Clermont FF, Letteboer TG, et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun 2012; 3:616.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/37\" class=\"nounderline abstract_t\">Letteboer TG, Benzinou M, Merrick CB, et al. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet 2015; 6:67.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/38\" class=\"nounderline abstract_t\">Pawlikowska L, Nelson J, Guo DE, et al. The ACVRL1 c.314-35A&gt;G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations. Am J Med Genet A 2015; 167:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/39\" class=\"nounderline abstract_t\">Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/40\" class=\"nounderline abstract_t\">Gu Y, Jin P, Zhang L, et al. Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia. Blood 2006; 107:1951.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/41\" class=\"nounderline abstract_t\">Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000; 26:328.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/42\" class=\"nounderline abstract_t\">Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008; 111:633.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/43\" class=\"nounderline abstract_t\">Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/44\" class=\"nounderline abstract_t\">Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90:818.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/45\" class=\"nounderline abstract_t\">Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010; 8:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/46\" class=\"nounderline abstract_t\">Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/47\" class=\"nounderline abstract_t\">Giordano P, Lenato GM, Suppressa P, et al. Hereditary hemorrhagic telangiectasia: arteriovenous malformations in children. J Pediatr 2013; 163:179.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/48\" class=\"nounderline abstract_t\">Shovlin CL, Awan I, Cahilog Z, et al. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol 2016; 215:179.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/49\" class=\"nounderline abstract_t\">Wallace GM, Shovlin CL. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 2000; 55:685.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/50\" class=\"nounderline abstract_t\">Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42:577.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/51\" class=\"nounderline abstract_t\">Plauchu H, de Chadar&eacute;vian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/52\" class=\"nounderline abstract_t\">Latino GA, Al-Saleh S, Alharbi N, et al. Prevalence of pulmonary arteriovenous malformations in children versus adults with hereditary hemorrhagic telangiectasia. J Pediatr 2013; 163:282.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/53\" class=\"nounderline abstract_t\">Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47:711.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/54\" class=\"nounderline abstract_t\">Sabb&agrave; C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006; 99:327.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/55\" class=\"nounderline abstract_t\">Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope 2013; 123:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/56\" class=\"nounderline abstract_t\">Elphick A, Shovlin CL. Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia. Laryngoscope 2014; 124:1521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/57\" class=\"nounderline abstract_t\">Hoag JB, Terry P, Mitchell S, et al. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120:838.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/58\" class=\"nounderline abstract_t\">Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121:636.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/59\" class=\"nounderline abstract_t\">Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95:415.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/60\" class=\"nounderline abstract_t\">Pasculli G, Quaranta D, Lenato GM, et al. Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia. QJM 2005; 98:757.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/61\" class=\"nounderline abstract_t\">Bharatha A, Faughnan ME, Kim H, et al. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012; 43:72.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/62\" class=\"nounderline abstract_t\">Lacout A, Pelage JP, Lesur G, et al. Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT. Radiology 2010; 254:479.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/63\" class=\"nounderline abstract_t\">Gefen AM, White AJ. Asymptomatic pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia. Pediatr Pulmonol 2017; 52:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/64\" class=\"nounderline abstract_t\">Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/65\" class=\"nounderline abstract_t\">Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205:531.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/66\" class=\"nounderline abstract_t\">Boother EJ, Brownlow S, Tighe HC, et al. Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations. Clin Infect Dis 2017; 65:595.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/67\" class=\"nounderline abstract_t\">Shovlin CL, Sodhi V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 2008; 115:1108.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/68\" class=\"nounderline abstract_t\">Post MC, Letteboer TG, Mager JJ, et al. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128:2485.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/69\" class=\"nounderline abstract_t\">Stephan MJ, Nesbit GM, Behrens ML, et al. Endovascular treatment of spinal arteriovenous fistula in a young child with hereditary hemorrhagic telangiectasia. Case report. J Neurosurg 2005; 103:462.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/70\" class=\"nounderline abstract_t\">Maher CO, Piepgras DG, Brown RD Jr, et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001; 32:877.</a></li><li class=\"breakAll\">http://www.ninds.nih.gov/news_and_events/news_articles/ARUBA_trial_results.htm (Accessed on August 02, 2013).</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/72\" class=\"nounderline abstract_t\">Buscarini E, Danesino C, Plauchu H, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 2004; 30:1089.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/73\" class=\"nounderline abstract_t\">Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008; 48:811.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/74\" class=\"nounderline abstract_t\">European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/75\" class=\"nounderline abstract_t\">Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343:931.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/76\" class=\"nounderline abstract_t\">DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/77\" class=\"nounderline abstract_t\">Buscarini E, Plauchu H, Garcia Tsao G, et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006; 26:1040.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/78\" class=\"nounderline abstract_t\">Caselitz M, Wagner S, Chavan A, et al. Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease). Gut 1998; 42:123.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/79\" class=\"nounderline abstract_t\">Fogerty RL, Greenwald JL, McDermott S, et al. Case 7-2017. A 73-Year-Old Man with Confusion and Recurrent Epistaxis. N Engl J Med 2017; 376:972.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/80\" class=\"nounderline abstract_t\">Buscarini E, Buscarini L, Civardi G, et al. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol 1994; 163:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/81\" class=\"nounderline abstract_t\">Buscarini E, Leandro G, Conte D, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56:2166.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/82\" class=\"nounderline abstract_t\">Vorselaars VM, Velthuis S, Snijder RJ, et al. Pulmonary hypertension in hereditary haemorrhagic telangiectasia. World J Cardiol 2015; 7:230.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/83\" class=\"nounderline abstract_t\">Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010; 181:851.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/84\" class=\"nounderline abstract_t\">Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med 2013; 368:876.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/85\" class=\"nounderline abstract_t\">Livesey JA, Manning RA, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67:328.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/86\" class=\"nounderline abstract_t\">Shovlin CL, Chamali B, Santhirapala V, et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One 2014; 9:e88812.</a></li><li class=\"breakAll\">Woods HF, Youdim MB, Boulllin D, Callender S. Monoamine metabolism and platelet function in iron-deficiency anaemia. In: Iron metabolism. In CIBA Foundation Symposium 51 (new series), Elsevier, Amsterdam 1977. p.227.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/88\" class=\"nounderline abstract_t\">HODGSON CH, BURCHELL HB, GOOD CA, CLAGETT OT. Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous fistula: survey of a large family. N Engl J Med 1959; 261:625.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/89\" class=\"nounderline abstract_t\">Steele JG, Nath PU, Burn J, Porteous ME. An association between migrainous aura and hereditary haemorrhagic telangiectasia. Headache 1993; 33:145.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/90\" class=\"nounderline abstract_t\">Marziniak M, Jung A, Guralnik V, et al. An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Cephalalgia 2009; 29:76.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/91\" class=\"nounderline abstract_t\">Thenganatt J, Schneiderman J, Hyland RH, et al. Migraines linked to intrapulmonary right-to-left shunt. Headache 2006; 46:439.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/92\" class=\"nounderline abstract_t\">Post MC, van Gent MW, Plokker HW, et al. Pulmonary arteriovenous malformations associated with migraine with aura. Eur Respir J 2009; 34:882.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/93\" class=\"nounderline abstract_t\">Post MC, Thijs V, Schonewille WJ, et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006; 66:202.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/94\" class=\"nounderline abstract_t\">Hosman AE, Devlin HL, Silva BM, Shovlin CL. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 2013; 8:195.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/95\" class=\"nounderline abstract_t\">Hanneman K, Faughnan ME, Prabhudesai V. Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Can Assoc Radiol J 2014; 65:135.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/96\" class=\"nounderline abstract_t\">Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/97\" class=\"nounderline abstract_t\">Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome/abstract/98\" class=\"nounderline abstract_t\">Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:73.</a></li><li class=\"breakAll\">Mcdonald J, Bayrak-Toydemir P, Whitehead A. Curacao Criteria highly predictive of a mutation in ACVRL1 or ENG. Proceedings of the 11th International HHT Scientific Conference, June 11-14, 2015; p.33.</li><li class=\"breakAll\">Available at 1-800-448-6389 or on the Foundation's website at http://curehht.org/ (Accessed on August 18, 2016).</li></ol></div><div id=\"topicVersionRevision\">Topic 1345 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H30\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DISEASE OVERVIEW</a></li><li><a href=\"#H104272142\" id=\"outline-link-H104272142\">INCIDENCE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">PATHOPHYSIOLOGY</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Disease-causing DNA sequence variants in HHT</a></li><li><a href=\"#H197304\" id=\"outline-link-H197304\">Genotype-phenotype correlations</a></li><li><a href=\"#H24973965\" id=\"outline-link-H24973965\">Cellular defects</a></li><li><a href=\"#H2524536\" id=\"outline-link-H2524536\">Vascular defects</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">CLINICAL FEATURES</a><ul><li><a href=\"#H615291\" id=\"outline-link-H615291\">Overview of clinical features</a></li><li><a href=\"#H18820894\" id=\"outline-link-H18820894\">Onset of disease manifestations</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Epistaxis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Gastrointestinal bleeding</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Mucocutaneous telangiectasia</a></li><li><a href=\"#H20480786\" id=\"outline-link-H20480786\">Sites of large arteriovenous malformations</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">- Pulmonary AVMs</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Cerebral AV shunts</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Hepatic involvement</a></li></ul></li><li><a href=\"#H1398318828\" id=\"outline-link-H1398318828\">Iron deficiency</a></li><li><a href=\"#H24974364\" id=\"outline-link-H24974364\">Pulmonary hypertension</a></li><li><a href=\"#H12131106\" id=\"outline-link-H12131106\">Venous thromboembolism</a></li><li><a href=\"#H3839692\" id=\"outline-link-H3839692\">Arterial thromboses and platelets</a></li><li><a href=\"#H3839749\" id=\"outline-link-H3839749\">Migraines</a></li><li><a href=\"#H3840081\" id=\"outline-link-H3840081\">Cancer frequency</a></li><li><a href=\"#H323011\" id=\"outline-link-H323011\">Laboratory findings</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIAGNOSIS</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Consensus criteria</a></li></ul></li><li><a href=\"#H12130735\" id=\"outline-link-H12130735\">RESOURCES</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H99154045\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H583517746\" id=\"outline-link-H583517746\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/1345|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/63662\" class=\"graphic graphic_diagnosticimage\">- Cerebral abscess with PAVM</a></li><li><a href=\"image.htm?imageKey=GAST/52754\" class=\"graphic graphic_diagnosticimage\">- Angiodysplasia colon angio</a></li><li><a href=\"image.htm?imageKey=PULM/56072\" class=\"graphic graphic_diagnosticimage\">- CT of a pulmonary arteriovenous malformation</a></li><li><a href=\"image.htm?imageKey=PULM/54651\" class=\"graphic graphic_diagnosticimage\">- PAVM angiogram I</a></li><li><a href=\"image.htm?imageKey=NEURO/53992\" class=\"graphic graphic_diagnosticimage\">- Dark flow void from AVM on MRI</a></li></ul></li><li><div id=\"HEME/1345|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/77416\" class=\"graphic graphic_picture\">- Mucosal telangiectasias in HHT</a></li><li><a href=\"image.htm?imageKey=GAST/50137\" class=\"graphic graphic_picture\">- Angiodysplasia endosc</a></li><li><a href=\"image.htm?imageKey=GAST/73541\" class=\"graphic graphic_picture\">- Colonic angiodysplasia Endosc</a></li><li><a href=\"image.htm?imageKey=PEDS/52483\" class=\"graphic graphic_picture\">- Osler Weber Rendu</a></li><li><a href=\"image.htm?imageKey=NEURO/75190\" class=\"graphic graphic_picture\">- AVM pretreatment angiography</a></li></ul></li><li><div id=\"HEME/1345|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/74593\" class=\"graphic graphic_table\">- Overview of HHT features and their management</a></li><li><a href=\"image.htm?imageKey=HEME/54074\" class=\"graphic graphic_table\">- Complications of pulmonary AVMs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=angiodysplasia-of-the-gastrointestinal-tract\" class=\"medical medical_review\">Angiodysplasia of the gastrointestinal tract</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-epistaxis\" class=\"medical medical_review\">Approach to the adult with epistaxis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">Clinical features and diagnosis of pulmonary hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-hemangioma\" class=\"medical medical_review\">Hepatic hemangioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=iron-deficiency-in-infants-and-children-less-than12-years-treatment\" class=\"medical medical_review\">Iron deficiency in infants and children &lt;12 years: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=iron-requirements-and-iron-deficiency-in-adolescents\" class=\"medical medical_review\">Iron requirements and iron deficiency in adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-epistaxis-in-children\" class=\"medical medical_review\">Management of epistaxis in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia\" class=\"medical medical_review\">Management of hereditary hemorrhagic telangiectasia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-clinical-manifestations-and-diagnosis-of-migraine-in-adults\" class=\"medical medical_review\">Pathophysiology, clinical manifestations, and diagnosis of migraine in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=arteriovenous-malformations-in-the-brain-the-basics\" class=\"medical medical_basics\">Patient education: Arteriovenous malformations in the brain (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-clinical-features-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-arteriovenous-malformations-epidemiology-etiology-and-pathology-in-adults\" class=\"medical medical_review\">Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secondary-findings-from-genetic-testing\" class=\"medical medical_review\">Secondary findings from genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-epidemiology-and-pathogenesis-of-pulmonary-arterial-hypertension-group-1\" class=\"medical medical_review\">The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">Therapeutic approach to adult patients with pulmonary arteriovenous malformations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Treatment of iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vascular-malformations-of-the-central-nervous-system\" class=\"medical medical_review\">Vascular malformations of the central nervous system</a></li></ul></div></div>","javascript":null}